Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials

por Nelson, Mark, Hill, Andrew, van Delft, Yvon, Moecklinghoff, Christiane
Publicado 2014

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial

por Geretti, Anna Maria, Moeketsi, Mathe, Demasi, Ralph, van Delft, Yvon, Mohammed, Perry
Publicado 2015

No Difference in the Rate of Change in Telomere Length or Telomerase Activity in HIV-Infected Patients after Three Years of Darunavir/Ritonavir with and without Nucleoside Analogue...

por Solomon, Ajantha, Tennakoon, Surekha, Leeansyah, Edwin, Arribas, Jose, Hill, Andrew, Van Delft, Yvon, Moecklinghoff, Christiane, Lewin, Sharon R.
Publicado 2014

The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL

por Antinori, Andrea, Arribas, Jose, Fehr, Jan, Girard, Pierre-Marie, Horban, Andrzej, Hill, Andrew, van Delft, Yvon, Moecklinghoff, Christiane, Hill, Andrew
Publicado 2014

Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV

por Munderi, Paula, Were, Edwin, Avihingsanon, Anchalee, Mbida, Pascale A.M., Mohapi, Lerato, Moussa, Samba B., Jansen, Marjolein, Bicer, Ceyhun, Mohammed, Perry, van Delft, Yvon
Publicado 2019